Sacituzumab Govitecan (SG) Clinical Trials
8 recruitingDrug
Phase 25Phase 13Phase 32Not Applicable1
Showing 1–8 of 8 trials
Recruiting
Phase 2
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
Urothelial Carcinoma
University of California, Irvine23 enrolled1 locationNCT06682728
Recruiting
Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Gilead Sciences695 enrolled205 locationsNCT06801834
Recruiting
Phase 1Phase 2
Saci Nivo Rela for TNBC
Metastatic Triple-negative Breast Cancer
Yale University60 enrolled1 locationNCT06963905
Recruiting
Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
Breast CancerTrop2Brain Metastases From Breast Cancer
Peking University Cancer Hospital & Institute100 enrolled1 locationNCT07251868
Recruiting
Phase 1Phase 2
Sacituzumab Govitecan Plus EV in Metastatic UC
Metastatic Urothelial CarcinomaUrothelial CancerBladder Cancer+1 more
Dana-Farber Cancer Institute106 enrolled1 locationNCT04724018
Recruiting
Phase 1Phase 2
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Triple Negative Locally Advanced Non-resectable Breast Cancer
Marengo Therapeutics, Inc.50 enrolled8 locationsNCT06827613
Recruiting
Not Applicable
Trop-2 Targeted PET Probes in Advanced TNBC
TNBC - Triple-Negative Breast Cancer
Peking University Cancer Hospital & Institute20 enrolled1 locationNCT07046455
Recruiting
Phase 2Phase 3
Sacituzumab Govitecan in Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
University Hospital Heidelberg80 enrolled1 locationNCT06243393